Breast Cancer Detection: New Technologies Push the Envelope
Technologies for breast cancer detection are evolving rapidly as manufacturers work to push the diagnostic envelope beyond standard screening mammography, ultrasound technology, and magnetic resonance imaging. At two recent meetings, the November 2010 meeting of the Radiology Society of North America and the March 2011 meeting of the European Congress of Radiology, several presentations focused on the latest research and technology developments in breast cancer detection.
You may also be interested in...
With the breast cancer screening population expected to reach almost 250 million by 2018, TiaLinx says its new AR60-A scanner is the first non-contact, high-resolution imaging technology that does not emit ionizing radiation, and is an affordable screening alternative for the 210,000 primary care physicians in the US and significantly more worldwide.
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.
Brief summaries of recent medtech market and industry developments. This month we cover recent device M&A, Medtronic and Nile Therapeutics' collaboration in heart failure, Neoprobe and Naviscan PET Systems' deal in cancer detection, and Qiagen and Epigenomics AG's collaboration in a blood test for colorectal cancer.